Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-56

I wonder if the analysts in the Australian market sometimes simply look at the title of an announcement rather than reading the first key dot points. To the analysts who skip it by, the heading refers to a conference but the dot points contain the strongest language to date. While stronger language may not have been appropriate in the context of the conference presentation using the words such as “new treatment for advanced cancer” as the announcement subject might have created more external interest but perhaps management also needs to be measured in view of FDA process. Just musing.